BIIB News 325.68 07/08/2014 04:31:47 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board

Jul 8, 2014 at 5:31 AM

Biogen Idec Inc (BIIB) 325.68 $BIIB

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

Integra Upbeat on DuraSeal Acquisition despite Tepid Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 2:10PM CDT
On Jul 3, 2014, we initiated coverage on Integra LifeSciences Holdings Corpopration (IART).

Biotechnology for the Non Biotechnologist Seminar - 22nd-24th September, London UK
M2 - Mon Jul 07, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sfvlxp/biotechnology_for) has announced the addition of the "Biotechnology for the Non Biotechnologist" conference to their offering. The Biotechnology for the Non Biotechnologist conference takes place on 22nd, 23rd and 24th September 2014 Location: The Rembrandt Hotel, London Topics to be covered at this course: Day One - Introduction to Biotechnology - Introduction to Molecular Biology - Re-Expression of Proteins - Development of Production Organisms - Fermentation Technology and Large Scale Production Day Two - Process Optimisation and Scale-Up - Analysis of Biopharmaceuticals - Product Recovery and Purification - Formulation Design of Biopharmaceuticals - Process Economics Day Three - Patenting Biotech Inventions - Patent Workshop - Regulatory Considerations - Application of Regulatory Principles - Advances in Regulation: Biosimilars - Advances in Regulation: Advanced Therapies WHY SHOULD YOU ATTEND? - Gain an introduction to the fundamental principles of biotechnology - Improve your understanding of the key techniques used by biotechnologists - Understand the importance of meeting regulatory requirements and hear about the advances being made - Learn how to identify potential patents, and why and how they must be protected - Share knowledge and experiences with fellow attendees from across Europe WHO SHOULD ATTEND? Personnel from: - Quality Assurance - Regulatory Affairs - Legal and IP - Business Development - Sales and Marketing - Engineering - Finance - Training - Administration - Management Previously attended by: - Astrazeneca Ab - Bayer Sa - Biogen Idec Ltd - Boehringer Ingleheim - Pharmaceuticals Inc. - Eli Lilly & Co Ltd - Genzyme Europe Bv - Merck Sharp & Dohme - Novartis Pharma Sa - Pfizer Global R&D - Reckitt Benckiser - Healthcare (UK) Ltd - Shire Pharmaceuticals - Ucb Sa For more information visit http://www.researchandmarkets.com/research/sf...nology_for

BIND Therapeutics (BIND) in Focus: Stock Tumbles 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:44AM CDT
BIND Therapeutics stock fell over 10% last trading session, reversing its recent trend

Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec
PR Newswire - Mon Jul 07, 4:55AM CDT
On Thursday, July 03, 2014, the NASDAQ Composite ended at 4,485.93, up 0.63%, the Dow Jones Industrial Average advanced 0.54%, to finish the day at 17,068.26, and the S&P 500 closed at 1,985.44, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index also advancing 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), InterMune Inc. (NASDAQ: ITMN), Cytokinetics Inc. (NASDAQ: CYTK) and Biogen Idec Inc. (NASDAQ: BIIB). Free technical research on ALXN, ITMN, CYTK and BIIB can be downloaded upon signing up at:

NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind
PR Newswire - Fri Jul 04, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.

Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 4:10PM CDT
Jazz Pharmaceuticals (JAZZ) announced that it has entered into an agreement to acquire the rights to defibrotide from Sigma-Tau Pharmaceuticals, Inc.

Genomic Grows on Breast Cancer Test, Margin Pressure Continues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 1:30PM CDT
On Jul 3, we issued an updated research report on Genomic Health Inc. (GHDX).

Sanofi and CureVac Ink Vaccine Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 12:36PM CDT
Sanofi (SNY) and Germany-based CureVac entered into an agreement for the development and commercialization of an mRNA-based vaccine against an undisclosed pathogen.

Insys Therapeutics' Epilepsy Therapy Gains FDA Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 10:30AM CDT
The FDA granted orphan drug status to Insys' (INSY) pharmaceutical cannabidiol, for treating Dravet syndrome.

Stock Market News for July 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 9:06AM CDT
Benchmarks ended Wednesday’s listless trading session little changed despite upbeat private sector hiring numbers

Vertex Pharmaceuticals Up on Kalydeco sNDA Submission - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 6:15PM CDT
Vertex Pharmaceuticals Inc (VRTX) filed a supplemental new drug application (sNDA) to the FDA for Kalydeco (ivacaftor) for R117H mutation.

Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.

Regeneron Shares Jump as Sanofi Increases Stake - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 10:30AM CDT
Sanofi (SNY) will control 22.5% of Regeneron (REGN) going forward.

Agenus Inc. (AGEN) Soars: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:18AM CDT
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares rise by over 10% on the day.

Strength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:44AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares surge nearly 20% on the day

RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.

Illumina Expands in Europe on 3 NIPT Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 5:05PM CDT
Illumina Inc. (ILMN) has entered into three separate partnership agreements with Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics Martinsrieduse.

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.99% Rise
Comtex SmarTrend(R) - Tue Jul 01, 4:39PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.24 to a high of $326.23. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $320.99 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...